Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17149869rdf:typepubmed:Citationlld:pubmed
pubmed-article:17149869lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:17149869lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:17149869lifeskim:mentionsumls-concept:C1621601lld:lifeskim
pubmed-article:17149869lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:17149869lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:17149869lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:17149869lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:17149869pubmed:issue25lld:pubmed
pubmed-article:17149869pubmed:dateCreated2006-12-7lld:pubmed
pubmed-article:17149869pubmed:abstractTextA novel series of melatonin receptor ligands was discovered by opening the cyclic scaffolds of known classes of high affinity melatonin receptor antagonists, while retaining the pharmacophore elements postulated by previously described 3D-QSAR and receptor models. Compounds belonging to the classes of 2,3- and [3,3-diphenylprop(en)yl]alkanamides and of o- or [(m-benzyl)phenyl]ethyl-alkanamides were synthesized and tested on MT(1) and MT(2) receptors. The class of 3,3-diphenyl-propenyl-alkanamides was the most interesting one, with compounds having MT(2) receptor affinity similar to that of MLT, remarkable MT(2) selectivity, and partial agonist or antagonist behavior. In particular, the (E)-m-methoxy cyclobutanecarboxamido derivative 18f and the di-(m-methoxy) acetamido one, 18g, have sub-nM affinity for the MT(2) subtype, with more than 100-fold selectivity over MT(1), 18f being an antagonist and 18g a partial agonist on GTPgammaS test. Docking of 18g into a previously developed MT(2) receptor model showed a binding scheme consistent with that of other antagonists. The MT(2) expected binding affinities of the new compounds were calculated by a previously developed 3D-QSAR CoMFA model, giving satisfactory predictions.lld:pubmed
pubmed-article:17149869pubmed:languageenglld:pubmed
pubmed-article:17149869pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:citationSubsetIMlld:pubmed
pubmed-article:17149869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17149869pubmed:statusMEDLINElld:pubmed
pubmed-article:17149869pubmed:monthDeclld:pubmed
pubmed-article:17149869pubmed:issn0022-2623lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:MateoM CMClld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:ScaglioneFran...lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:BediniAnnalid...lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:TarziaGiorgio...lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:SpadoniGilber...lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:GattiGiuseppe...lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:LuciniValeria...lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:PannacciMaril...lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:RivaraSilviaSlld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:LodolaAlessio...lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:LucariniSimon...lld:pubmed
pubmed-article:17149869pubmed:authorpubmed-author:LorenziSimone...lld:pubmed
pubmed-article:17149869pubmed:issnTypePrintlld:pubmed
pubmed-article:17149869pubmed:day14lld:pubmed
pubmed-article:17149869pubmed:volume49lld:pubmed
pubmed-article:17149869pubmed:ownerNLMlld:pubmed
pubmed-article:17149869pubmed:authorsCompleteYlld:pubmed
pubmed-article:17149869pubmed:pagination7393-403lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:meshHeadingpubmed-meshheading:17149869...lld:pubmed
pubmed-article:17149869pubmed:year2006lld:pubmed
pubmed-article:17149869pubmed:articleTitleDesign and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.lld:pubmed
pubmed-article:17149869pubmed:affiliationIstituto di Chimica Farmaceutica e Tossicologica, Università degli Studi di Urbino Carlo Bo, Piazza Rinascimento 6, 61029 Urbino, Italy.lld:pubmed
pubmed-article:17149869pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17149869pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17149869lld:chembl